Lawrence Livermore National Laboratory announced this week a new collaboration with a United Kingdom company to develop a broad-spectrum or "universal" coronavirus vaccine.
Date Time
LLNL and United Kingdom company to collaborate on development of universal coronavirus vaccine
LLNL researchers Nick Fischer and Amy Rasley are characterizing nanolipoprotein particle vaccine formulations using a dynamic light-scattering instrument. Detailed characterization of the nanoparticles provides an important quality control metric for vaccine development. A United Kingdom company, ConserV Bioscience Limited, and LLNL have agreed to work on developing a universal coronavirus vaccine. Photo by Julie Russell/LLNL (taken pre-pandemic).
ConserV Bioscience Limited (CBL) and Lawrence Livermore National Laboratory (LLNL) have agreed to collaborate on the development of a broad-spectrum or “universal” coronavirus vaccine.
This collaboration brings together CBL’s expertise in identifying antigens and LLNL’s nanolipoprotein delivery system. The vaccine has been designed to provide broad-spectrum protection against coronavirus pathogens of human and animal origin,
In the recent oath-taking ceremony of newly conferred and upgraded scientists, DOST Secretary Dr. Fortunato T. Dela Peña commends PhilRice after three of its experts landed in this year’s ranking.
“[With 12 scientists nine Scientist I and three Scientist II], PhilRice has the highest number of active career scientists. I appreciate the newly conferred and upgraded scientists for their dedication and significant contributions to research in their respective areas of expertise,” he said.
Dr. Aurora M. Corales and Dr. Elmer G. Bautista were conferred the Scientist I rank, while Dr. Norvie L. Manigbas was upgraded to Scientist II rank by the Scientific Career Council.